EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab–Bevacizumab

Filiz Araz iD, Fatih Köse iD, Timuçin Çil iD, Berna Bozkurt Duman iD, Burcu Arslan Benli iD, Elif Karadeli iD, Okan Dilek iD

Journal of Hepatocellular Carcinoma · 2026-08 · Volume 13 · 1-12

DOI: 10.2147/jhc.s617103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-08. Verfasst von Filiz Araz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Başkent University Adana Dr. Turgut Noyan Training and Research Hospital, Adana, Türkiye. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

ALBIatezolizumabbevacizumabhepatocellular carcinoma

Autor:innen und Institutionen

  • Gastroenterology, Başkent University Adana Dr. Turgut Noyan Training and Research Hospital, Adana, Türkiye.
  • Medical Oncology, Başkent University Adana Dr. Turgut Noyan Training and Research Hospital, Adana, Türkiye.
  • Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.
  • Medical Oncology, Adana City Training and Research Hospital, Adana, Türkiye.
  • Radiology, Başkent University Adana Dr. Turgut Noyan Training and Research Hospital, Adana, Türkiye.
  • Radiology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Türkiye.

ORCID-Profile: Filiz Araz, Fatih Köse, Timuçin Çil, Berna Bozkurt Duman, Burcu Arslan Benli, Elif Karadeli, Okan Dilek

Zitieren

APA

Araz, F., Köse, F., Çil, T., Bozkurt Duman, B., Arslan Benli, B., Karadeli, E., & Dilek, O. (2026). Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab–Bevacizumab. Journal of Hepatocellular Carcinoma, Volume 13, 1-12. https://doi.org/10.2147/jhc.s617103

Vancouver

Araz F, Köse F, Çil T, Bozkurt Duman B, Arslan Benli B, Karadeli E, et al. Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab–Bevacizumab. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-12. doi:10.2147/jhc.s617103

BibTeX
@article{Araz2026,
  author = {Araz, Filiz and Köse, Fatih and Çil, Timuçin and Bozkurt Duman, Berna and Arslan Benli, Burcu and Karadeli, Elif and Dilek, Okan},
  title = {Baseline ALBI Grade as an Independent Prognostic Factor of Survival in High-Risk Real-World HCC Under Atezolizumab–Bevacizumab},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--12},
  doi = {10.2147/jhc.s617103}
}
Kostenlos starten →